Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5031005 | 0.74 | MEN1 (0.58) | MAPTRAB9ALMNAL3MBTL1NPC1 | |
| SCHEMBL5031002 | 0.74 | MEN1 (0.58) | MAPTRAB9ALMNAL3MBTL1NPC1 | |
| SCHEMBL9655956 | 0.72 | MAPT (0.63) | MAPTRAB9ALMNANPC1MEN1 | |
| SCHEMBL9655953 | 0.72 | MAPT (0.63) | MAPTRAB9ALMNANPC1MEN1 | |
| SCHEMBL10335322 | 0.72 | MAPT (0.63) | MAPTRAB9ALMNANPC1MEN1 | |
| SCHEMBL14757299 | 0.71 | MAPT (0.75) | MAPTRAB9ALMNAL3MBTL1NPC1 | |
| SCHEMBL14107064 | 0.69 | MEN1 (0.43) | MAPTRAB9ALMNAL3MBTL1NPC1 | |
| SCHEMBL10511247 | 0.68 | RAB9A (0.74) | MAPTRAB9ALMNANPC1MEN1 | |
| SCHEMBL31005089 | 0.67 | MAPT (0.78) | MAPTRAB9ALMNAL3MBTL1NPC1 | |
| SCHEMBL14757390 | 0.66 | MAPT (1.00) | MAPTRAB9ALMNAL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | MAPT 4421/4885RAB9A 2563/4885LMNA 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.